Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of [14C]-Evobrutinib in Healthy Participants
NCT03725072Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evobrutinib in multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), sponsored by Merck KGaA. Primary endpoints: Total Radioactivity Recovery Rate of Evobrutinib, Total Radioactivity and its Metabolites, Percentage Excretion of Evobrutinib, Total Radioactivity and its Metabolites in Urine and Feces and 11 more. Started Oct 2018; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03725072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725072.